1. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection;Fahim AT;JAMA,2014
2. Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin
3. Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes
4. FDA approves Jetrea for symptomatic vitreomacular adhesion in the eyes [press release]. US Food and Drug Administration; October 18 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/ucm324369.htm. Accessed August 3 2013.
5. Ocriplasmin (Jetrea) briefing document. Dermatologic and Ophthalmic Drugs Advisory Committee; July 26 2012. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/dermatologicandophthalmicdrugsadvisorycommittee/ucm313091.pdf. Accessed August 3 2013.